Biotech hope gets DKK 24 million from US venture fund, Væsktfonden and others

Antag Therapeutics, which is developing a treatment for obesity and diabetes with the help of the man who discovered GLP-1 hormones, has gained some new investors.

Alexander Hovard Sparre-Ulrich, co-founder and CEO of Antag Therapeutics Photo: Antag Therapeutics/PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles